COMMUNIQUÉS West-GlobeNewswire
-
Provincial funding will expand access to team-based primary care in North Western Toronto
15/09/2026 -
Correction: IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026
15/09/2026 -
Correction: IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 36 - 2026
15/09/2026 -
Elevar Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Lirafugratinib as a Treatment for Patients with Advanced/Metastatic Cholangiocarcinoma (CCA) Harboring FGFR2 Fusions or Rearrangements
15/09/2026 -
FemPulse Clinical Data to be Presented at ICS on October 9
15/09/2026 -
USAHS Brings Healthcare Professionals Together to Spark Action on Workplace Mental Health
15/09/2026 -
Patterson Veterinary Launches Atlas: an AI Assistant for Veterinary Software
15/09/2026 -
Er-Kim Announces Positive Reimbursement Decision in the Czech Republic for Vafseo® (vadadustat) to Treat Symptomatic Anaemia in Adult CKD Dialysis Patients
15/09/2026 -
Shriners Hospitals for Children Canada Achieves a National First in Pediatric Motion Analysis
15/09/2026 -
Les Hôpitaux Shriners pour enfants Canada réalisent une première nationale en analyse du mouvement pédiatrique
15/09/2026 -
Reflect Scientific Announces Liquid Nitrogen Cooling Technology for AI Data Center Applications
15/09/2026 -
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
15/09/2026 -
Egle Therapeutics to Present Clinical Data at the Upcoming European Academy of Dermatology and Venereology (EADV) Congress in Vienna
15/09/2026 -
FDA Launches Expedited IND Pilot, Begins Accepting Applications
15/09/2026 -
AscellaHealth Advances AscellaOne Technology Strategy, Names Asad Shoostry Chief Technology Officer
15/09/2026 -
Lanier Recovery Center earns Joint Commission accreditation
15/09/2026 -
AliveCor Launches KardiaACCESS: A Medicare-Covered Program Built to Improve Blood Pressure, Diabetes, and Heart Health
15/09/2026 -
Le KFSH de Riyad ne relève aucun constat à haut risque sur près de 1 800 critères évalués lors du renouvellement de son accréditation JCI
15/09/2026 -
Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus
15/09/2026
Pages